MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Roche Holding AG Company Profile (OTCMKTS:RHHBY)

Consensus Ratings for Roche Holding AG (OTCMKTS:RHHBY) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $177.50

Analysts' Ratings History for Roche Holding AG (OTCMKTS:RHHBY)
Show:
DateFirmActionRatingPrice TargetActions
5/13/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/1/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2016Piper Jaffray Cos.Initiated CoverageOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/20/2015Cowen and CompanyDowngradeOutperform -> Market Perform$42.00 -> $35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/13/2015Credit Suisse Group AGReiterated RatingOutperform$320.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015Baader BankUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/25/2015HSBCInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2015Erste GroupInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/13/2015Liberum CapitalDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/28/2015Bryan, Garnier & CoUpgradeBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/25/2014BNP ParibasInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2014Kepler Capital MarketsDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Roche Holding AG (OTCMKTS:RHHBY)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Roche Holding AG (OTCMKTS:RHHBY)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Roche Holding AG (OTCMKTS:RHHBY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Roche Holding AG (OTCMKTS:RHHBY)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Roche Holding AG (OTCMKTS:RHHBY)
DateHeadline
06/29/16 02:20 PMRoche's Multiple Sclerosis Drug Under Review by FDA, EMA -
06/28/16 06:02 PMRoche Holding Ltd. (RHHBY) Updated Price Targets - FTSE News
06/28/16 12:49 PM[video]Instead of Panicking on Brexit, Buy These Stocks -
06/27/16 10:16 AMWere Analysts Bearish Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) This Week? - Press Telegraph
06/23/16 06:43 PMNew Broker Ratings For Roche Holding Ltd. (RHHBY) - FTSE News
06/23/16 07:32 AMEpizyme Teams Up with Roche's Genentech for Tazemetostat -
06/22/16 01:31 PMRoche CEO 'sleeps better' as risk to drugmaker's growth recedes -
06/20/16 07:41 AMRoche : launches the new cobas e 801 module, helping hospitals meet the demand for increased diagnostic testing
06/16/16 06:21 PMRoche : Gazyvaro approved in Europe in combination with bendamustine for people with previously treated follicular lymphoma
06/16/16 07:15 AMMerck Extends Cancer Immunotherapy Reach to First-Line Lung Cancer -
06/15/16 06:01 PMRoche Holding Ltd. Ready to Enter IL-6 Antagonist Antibody Technology - Business Finance News
06/13/16 09:57 AMEleven Biotherapeutics Inc (EBIO) Soars on Roche Holding Ltd. (ADR) Deal - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Eleven Biotherapeutics stock soared on Monday following news of its deal with Roche concerning its Interleukin-6 technology. The post Eleven Biotherapeutics Inc (EBIO) Soars on Roche Holding Ltd. (ADR) Deal appeared first on InvestorPlace.
06/08/16 09:08 AMRoche : receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer
06/06/16 06:03 PMRoche : Genentech's Cancer Immunotherapy Tecentriq (Atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer
06/06/16 06:03 PMCombination Treatment Could Heighten Pricing Pressures On Johnson & Johnson (NYSE:JNJ)?
06/06/16 03:49 PMRoche Presents Encouraging Data on Actemra and Tecentriq -
06/06/16 11:53 AMPhase III Study Shows Genentech’s Actemra® (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA) - [Business Wire] - Genentech, a member of the Roche Group , today announced positive results from the Phase III study known as GiACTA, which evaluated Actemra® in people with giant cell arteritis .
06/06/16 09:49 AMRoche : cancer immunotherapy Tecentriq (atezolizumab) shrank tumours in people with previously untreated advanced bladder cancer
06/04/16 06:30 AMStudy finds targeted cancer drugs may work in range of tumor types - [Reuters] - Early results from a clinical trial of Roche Holding AG cancer drugs released on Saturday suggest some promise in matching treatments based on abnormalities found in a patient's tumor rather than the organ in which the cancer was originally detected. The findings, presented at the annual meeting of the American Society of Clinical Oncology in Chicago, showed that 29 out of 129 patients with 12 different types of advanced cancers responded to drugs targeting genetically driven abnormalities. The drugs were administered outside of indications currently approved by the U.S. Food and Drug Administration, which generally reviews drugs using studies based on the type of organ where the cancer was found.
06/03/16 06:07 PMStudy Finds Mylan's 'Biosimilar' Drug Comparable to Roche Cancer Medicine -
06/01/16 05:29 PMFDA Grants First Liquid Biopsy Approval to the Roche cobas® EGFR Mutation Test v2 - [PR Newswire] - PLEASANTON, Calif., June 1, 2016 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the cobas ® EGFR Mutation Test v2 for use ...
06/01/16 09:02 AMPromising Lupus Drug From XTL Could Be Life Changer In Projected $4 Billion Market - Seeking Alpha - Seeking AlphaPromising Lupus Drug From XTL Could Be Life Changer In Projected $4 Billion MarketSeeking AlphaXTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) poses a potential solution with its drug hCDR1 designed to battle systemic lupus erythematosus (SLE), accounting for 70% of lupus cases and intended to treat not just lupus' manifestations, but the disease itself.
06/01/16 07:47 AMSwiss biotech AC Immune taps U.S. IPO to fund Alzheimer's drugs - [Reuters - UK Focus] - Switzerland's AC Immune, which already has money in hand from Roche for its most advanced drug, is planning a share sale in the United States to raise up to $50 million for separate drug candidates targeting Alzheimer's disease. The company, run by former Nestle (VTX: NESN.VX - news) global research head Andrea Pfeifer, joins other European biotech firms that have opted to list in New York to tap the deeper pool of capital available in the United States and the presence of more specialist investors. British cancer immunotherapy firm Adaptimmune also opted for a Nasdaq (NasdaqGS: NDAQ - news) listing last year, while cannabis drugmaker GW Pharmaceuticals (LSE: GWP.L - news) and French allergy company DBV Technologies have both had successful U.S (Other OTC: UBGXF - news) .
05/31/16 09:42 AMRoche Holding Ltd. (ADR) (OTCMKTS:RHHBY) Announces Positive Phase3 Results From Gazyva - Journal Transcript - Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) Announces Positive Phase3 Results From GazyvaJournal TranscriptRoche Holding Ltd. (ADR) (OTCMKTS:RHHBY) has announced positive results, from the phase3 GALLIUM study, being conducted by its member company, Genentech. The study focuses on the treatment of patients with untreated follicular lymphoma, using ...
05/31/16 09:10 AMRoche's Subcutaneous Formulation of MabThera Gets EU Nod -
05/30/16 10:13 PMNext Weeks Broker Price Targets For Roche Holding Ltd. (RHHBY) - Share Trading News - Next Weeks Broker Price Targets For Roche Holding Ltd. (RHHBY)Share Trading News07/08/2014 – Roche Holding Ltd. had its “neutral” rating reiterated by analysts at Zacks. They now have a USD 39 price target on the stock. 01/30/2014 – Roche Holding Ltd. was downgraded to “neutral” by analysts at Natixis. Roche Holding Ltd. has a 50 ...Were Analysts Bullish Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) This Week?The Postall 2 news articles »
05/30/16 11:32 AMThese 5 Big Pharma Stocks Are Ridiculously Cheap - Motley Fool - Motley FoolThese 5 Big Pharma Stocks Are Ridiculously CheapMotley Fool(NYSE:MRK), Novartis (NYSE:NVS), Pfizer (NYSE:PFE), and Roche (NASDAQOTH:RHHBY) are trading at clearance rack prices. Let's take a .... Like Novartis, Roche pays annually, and has increased its distribution, in Swiss Francs, for 29 consecutive years.and more »
05/28/16 09:53 AMRoche's Hematology Franchise Almost 100% Protected From Biosimilars - Seeking Alpha - Seeking AlphaRoche's Hematology Franchise Almost 100% Protected From BiosimilarsSeeking AlphaRoche (OTCQX:RHHBY) has announced this morning positive data for the GALLIUM study. This study evaluates Gazyva vs. Rituxan in the first-line indolent Non-Hodgkin Lymphoma (iNHL). Roche has stopped the clinical study at interim results, which are a ...and more »
05/27/16 10:58 AMRoche's Gazyva beats Rituxan in late-stage lymphoma study - Seeking Alpha - Roche's Gazyva beats Rituxan in late-stage lymphoma studySeeking AlphaInterim data from a Phase 3 study, GALLIUM, show Genentech's (OTCQX:RHHBY) Gazyva (obinutuzumab) significantly reduced the risk of disease progression or death compared to Rituxan (rituximab) in treatment-naive follicular lymphoma patients. The trial ...and more »
05/27/16 10:58 AMBetter Buy: Regeneron Pharmaceuticals, Inc. vs. Roche - Motley Fool - Motley FoolBetter Buy: Regeneron Pharmaceuticals, Inc. vs. RocheMotley Fool... Roche (NASDAQOTH:RHHBY) isn't one taken lightly. Regeneron is growing sales and its pipeline at a breathtaking pace, but the Tarrytown, New York, biotech is also heavily dependent on a single drug at the moment. Meanwhile, Swiss behemoth Roche ...and more »
05/26/16 05:04 AMRoche CMV test for HSCT patients approved in US - Seeking Alpha - Roche CMV test for HSCT patients approved in USSeeking AlphaThe FDA approves Roche's (OTCQX:RHHBY) cytomegalovirus (CMV) test specifically targeted to patients who have undergone a hematopoietic stem cell transplant (HSCT). The real-time polymerase chain reaction (PCR)-based assay is designed to use on ...and more »
05/26/16 05:04 AMNovartis' CEO Says Company Open To Selling Its $14 Billion Stake In Roche 'If The Opportunity Were Right' - Yahoo News - Yahoo NewsNovartis' CEO Says Company Open To Selling Its $14 Billion Stake In Roche 'If The Opportunity Were Right'Yahoo NewsSwitzerland-based Novartis AG (ADR) (NYSE: NVS) owns a roughly $14 billion stake in rival Roche Holding Ltd. (ADR) (OTC: RHHBY) and is actively shopping for buyers to acquire its stake. According to Reuters, Novartis has been working with bankers to ...and more »
05/26/16 05:04 AMBroker Roundup For Roche Holding Ltd. (RHHBY) - Share Trading News - Broker Roundup For Roche Holding Ltd. (RHHBY)Share Trading News01/30/2014 – Roche Holding Ltd. was downgraded to “neutral” by analysts at Natixis. The share price of Roche Holding Ltd. (RHHBY) was up +0.75% during the last trading session, with a day high of 31.75. 723639 shares were traded on Roche Holding ...
05/25/16 09:07 AMNovartis' CEO Says Company Open To Selling Its $14 Billion Stake In Roche 'If The Opportunity Were Right' - Switzerland-based Novartis AG (ADR) (NYSE: NVS) owns a roughly $14 billion stake in rival Roche Holding Ltd. (ADR) (OTC: RHHBY) and is actively shopping for buyers to acquire its stake. According to Reuters, Novartis has been working with bankers to explore the sale of its stake ...Full story available on Benzinga.com
03/14/16 01:53 PMIn The Fight Against Cancer, Roche And AstraZeneca Are Looking At Trillions Of Bacteria That Live In The Body - Top scientists at Roche Holding Ltd. (ADR) (OTC: RHHBY) and AstraZeneca plc (ADR) (NYSE: AZN) are studying the possibilities of using bacteria in gut to fight cancer, according to a report on Bloomberg. Drugmakers are showing interest in the human ...
02/26/16 10:33 AMFDA Approves Genentech’s Gazyva® (Obinutuzumab) for Certain People with Previously Treated Follicular Lymphoma - [Business Wire] - Genentech, a member of the Roche Group , today announced that the U.S. Food and Drug Administration approved Gazyva® plus bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a Rituxan® -containing regimen, or whose follicular lymphoma returned after such treatment.
02/26/16 10:26 AMRoche Holding Ltd. (RHHBY) New Analyst Ratings - Share Trading News - Roche Holding Ltd. (RHHBY) New Analyst RatingsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Roche Holding Ltd. (RHHBY). The latest reports which are currently in issue on Friday 26th of February state 2 analysts have a rating of “strong buy”, 0 analysts “buy ...
02/26/16 09:45 AMCelldex's Q4 Loss Narrower than Expected; Focus on Pipeline -
02/11/16 10:16 AMIncyte Plummets After Stopping Trial Of Jakafi In Pancreatic Cancer -
02/08/16 01:06 PMRoche Holding Ltd. (RHHBY) Recent Analyst Updates - Risers & Fallers - Roche Holding Ltd. (RHHBY) Recent Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Roche Holding Ltd. (RHHBY). According to the latest broker reports outstanding on Monday 8th February, 2 analysts have a rating of “strong buy”, 0 analysts “buy”, ...
02/05/16 10:43 AMRoche Holding AG Earnings Analysis: 2015 By the Numbers -
02/04/16 12:04 PMROCHE HOLDING LTD /FI Financials -
02/02/16 12:47 PMRoche's Stock May Have Been Down, But The Company's Business Has Strong Outlook -
02/01/16 10:03 AM11:03 am Roche Hldg announces that updated cervical cancer screening guidelines from the College support the use of its cobas HPV Test for primary cervical cancer screening as an alternative -
02/01/16 10:00 AMUpdated cervical cancer screening guidelines from leading ob-gyn society support expanded use of cobas HPV Test for primary screening - [PR Newswire] - OTCQX: RHHBY) announced today that recently updated cervical cancer screening guidelines from the American College of Obstetricians and Gynecologists (The College) support the use of its cobas HPV Test for primary cervical cancer screening as an alternative to current cytology-based cancer screening methods (the Pap test) in women 25 and older. The College's revised Practice Bulletin 157, published in the January issue of Obstetrics & Gynecology, reinforces similar guidance issued in 2015 by the Society for Gynecologic Oncology (SGO) and the American Society for Colposcopy and Cervical Pathology (ASCCP). "As cervical cancer screening methods continue to improve, we are pleased to see recommendations for women's health care being updated in order to provide the best care for patients," said Alan Wright, MD, MPH, chief medical officer at Roche Diagnostics.
01/29/16 12:06 PMRoche Holding Ltd. (ADR) (OTCMKTS:RHHBY) 2016 Outlook Misses Estimates - Inside Stock Trader - Inside Stock TraderRoche Holding Ltd. (ADR) (OTCMKTS:RHHBY) 2016 Outlook Misses EstimatesInside Stock TraderSwiss drug maker Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY) could be in trouble after reporting full-year profit that missed analyst estimates and guiding slightly below estimates. The company expects sales to rise at a low-to-mid single digit percentage ...
01/27/16 11:31 AMWhat Can Investors Expect from Regeneron’s 4Q15 Earnings? -
01/22/16 07:42 AMCoverage initiated on Roche Hldg by Piper Jaffray -
01/21/16 06:21 PMVeeva: Why We Went Long Our Former Favorite Short - Seeking Alpha - Veeva: Why We Went Long Our Former Favorite ShortSeeking AlphaWith this in mind, Informatica seems to be doing a far better job holding onto their market share in this space versus EMC in content management. ... The three top 5 pharmas that stood out were Sanofi (NYSE:SNY), Roche (OTCQX:RHHBY), and GSK (NYSE:GSK ...
01/20/16 06:23 PMDrug and Diagnostic Companies Issue Joint Declaration on Antibiotics - Wall Street Journal - Drug and Diagnostic Companies Issue Joint Declaration on AntibioticsWall Street JournalMore than 80 drug and diagnostic companies have committed to working together to develop new antibiotics, while calling on governments to improve the financial incentives for doing so, in a declaration released at the World Economic Forum in Davos, ...and more »
About Roche Holding AG

Roche Holding AG logoRoche Holding AG is a research-based healthcare company. The Company develops, manufactures and delivers medicines, and diagnostic instruments and tests. Its operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. Its Pharmaceuticals division consists of two business segments: Roche Pharmaceuticals and Chugai. Its Diagnostics division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. It develops medicines for the disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its product portfolio consists of Pharmaceuticals, Solutions for Diagnostics and Products for Researchers. Its Pharmaceutical products include ACTEMRA and CellCept. Its Solutions for Diagnostics products include Accu-Chek Active System and Accu-Chek Aviva Nano System. The Company's Products for Researchers include Cedex HiRes and Genome Sequencer FLX System.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: RHHBY
  • CUSIP:
Key Metrics:
  • Previous Close: $32.86
  • 50 Day Moving Average: $32.02
  • 200 Day Moving Average: $32.09
  • P/E Ratio: 24.61
  • P/E Growth: 2.14
  • Market Cap: $223.96B
  • Current Quarter EPS Consensus Estimate: $1.89 EPS
Additional Links:
Roche Holding AG (OTCMKTS:RHHBY) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha